99mTC-MAMA-chrysamine G, a probe for beta-amyloid protein of Alzheimer's disease

European Journal of Nuclear Medicine

Volumn 26, Issue 11, 1999, Pages 1392-1399

  Dezutter, Nancy A ^a   Dom, René J ^b   De Groot, Tjibbe J ^a   Bormans, Guy M ^a   Verbruggen, Alfons M ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Alzheimer's disease; Chrysamine G; Congo red; Diagnosis; Technetium 99m

Indexed keywords

AMYLOID BETA PROTEIN; CHRYSAMINE G MONOAMIDE MONOAMINEDITHIOL TC 99M CONJUGATE; CONGO RED; SERUM ALBUMIN I 125; TECHNETIUM 99M; TRACER; UNCLASSIFIED DRUG; 99MTC MAMA CHRYSAMINE G; 99MTC-MAMA-CHRYSAMINE G; BENZOIC ACID DERIVATIVE; BIPHENYL DERIVATIVE; CHRYSAMINE G; COLORING AGENT; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; TECHNETIUM; TECHNETIUM COMPLEX;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPSY; AUTORADIOGRAPHY; BLOOD; BLOOD BRAIN BARRIER; BLOOD VESSEL; BRAIN; DRUG CLEARANCE; HEPATOBILIARY SYSTEM; HOMOGENATE; MOUSE; NONHUMAN; OCCIPITAL CORTEX; PARENCHYMA; PROTEIN BINDING; ADULT; AGED; ANIMAL; FEMALE; HUMAN; ISOTOPE LABELING; MALE; METABOLISM; MIDDLE AGED; MOUSE STRAIN; SCINTISCANNING; TISSUE DISTRIBUTION;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BENZOATES; BIPHENYL COMPOUNDS; BRAIN; COLORING AGENTS; FEMALE; HUMANS; ISOTOPE LABELING; MALE; MICE; MICE, INBRED STRAINS; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; TECHNETIUM; TISSUE DISTRIBUTION;

EID: 0032585931     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050470     Document Type: Article

References (35)

1. Cras P. Differential diagnosis in dementia. Acta Neurol Belg 1998; 98: 186-189.
2. Lendon CL, Ashall F, Goate AM. Exploring the etiology of Alzheimer's disease using molecular genetics. JAMA 1997; 277: 825-831.
3. Berchtold NC, Cotman CW. Evolution in the conceptualisation of dementia and Alzheimer's disease: Greco-Roman period to the 1960's. Neurobiol Aging 1998; 19: 173-189.
4. Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, Hebert LE, Hennekens CH, Taylor JO. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 1989; 262: 2551-2556.
5. Katzman R. Education and the prevalence of Alzheimer's disease. Neurology 1993; 43: 13-20.
6. Joachim CL, Morris JH, Selkoe DJ. Clinically diagnosed Alzheimer's disease: autopsy results in 150 cases. Ann Neurol 1988; 24: 50-56.
7. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
8. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985; 42:1097-1105.
9. Mirra SS, Heyman A, McKeel DW, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, Van Bell G, Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardisation of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-486.
10. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualisation of A beta 42(43) and A beta 40 in senile plaques with end-specific. A beta monoclonals: evidence that an initially deposited species is A beta 42 (43). Neuron 1994; 13: 45-53.
11. Mori H, Takio K, Ogawara M, Selkoe DJ. Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. J Biol Chem 1992; 267: 17082-17086.
12. 4 peptides of Alzheimer's disease. J Mol Biol 1991; 218: 149-163.
13. 4 amyloid in Alzheimer's disease brain for application to in vivo imaging of amyloid angiopathy. J Nucl Med 1992; 33: 2184-2189.
14. Friedland RP, Majocha RE, Reno JM, Lyle LR, Marotta CA. Development of an anti-Aβ monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease. Mol Neurobiol 1994; 9:107-113.
15. Walker LC, Price DL, Voytko ML, Schenk DB. Labelling of cerebral amyloid in vivo with a monoclonal antibody. J Neuropathol Exp Neurol 1994; 53: 377-383.
16. 4 protein: a potential probe for Alzheimer's disease. Bioconjugate Chem 1994; 5: 119-125.
17. Kalaria RN. The blood-brain barrier and cerebral microcirculation in Alzheimer's disease. Cerebrovasc Brain Metab Rev 1992; 4: 226-260.
18. Triguero D, Buciak JB, Yang J, Pardridge WM. Blood-brain barrier transport of cationised immunoglobulin G: enhanced delivery compared to native protein. Proc Natl Acad Sci USA 1989; 86: 4761-4765.
19. 1-40/vector complex. Proc Natl Acad Sci USA 1995; 92: 10227-10231.
20. Klunk WE, Debnath ML, Pettegrew JW. Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease. Neurobiol Aging 1994; 15: 691-698.
21. Klunk WE, Debnath ML, Pettegrew JW. Chrysamine-G binding to Alzheimer and control brain: autopsy study of a new amyloid probe. Neurobiol Aging 1995; 16: 541-548.
22. Han H, Cho C-G, Lansbury PT. Technetium complexes for the quantitation of brain amyloid. J Am Chem Soc 1996; 118: 4506-4507.
23. Mathis CA, Mahmood K, Debnath ML, Klunk WE. Synthesis of a lipophilic, radioiodinated ligand with high affinity to amyloid protein in Alzheimer's disease brain tissue. J Labelled Cpd Radiopharm 1997; 40: 94-95.
24. Klunk WE, Hamilton RL, Styren SD, Styren G, Debnath ML, Mathis CA, Mahmood K, Hsiao KK. Staining of AD and Tg2576 mouse brain with X-34, a highly fluorescent derivative of chrysamine G and a potential in vivo probe for β-sheet fibrils. Soc Neurosci Abstr 1997; 23: 1638.
25. Klunk WE, Hamilton RL, Styren SD, Styren G, Debnath ML. Neuropathological study of AD brain with X-34, a new, highly fluorescent derivative of Congo red. Soc Neurosci Abstr 1998; 24: 264.
26. Bennhold H. Üher die Ausscheidung intravenös einverleibter Kongorotes bei den verchiedensten Erkrankungen insbesondere bei Amyloidosis. Dtsch Arch Klin Med 1923; 142: 32-46.
27. Tavan A, Eckstein A. Standardisation of the Congo red test for amyloidosis. Am J Med Sci 1942; 203: 246-253.
28. Tubis M, Blahd WH, Nordyke RA. The preparation and use of radioiodinated Congo red in detecting amyloidosis. J Am Pharm Assoc 1960; 49: 422-425.
29. 35) labelled Congo red dye. J Nucl Med 1960; 1: 23-30.
30. Klunk WE, Pettegrew JW, Abraham DJ. Quantitative evaluation of Congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. J Histochem Cytochem 1989; 37: 1273-1281.
31. 2 conjugates of chrysamine G, potential probes for the beta-amyloid protein of Alzheimer's disease. J Labelled Cpd Radiopharm 1999; 42: 309-324.
32. 99mTc-N,N′-bis-(mercaptoacetamido)ethylenediamine. Effect of renal tubular inhibitors. Int J Nucl Med Biol 1982; 9: 79-82.
33. Puchtler H, Sweat F, Levine M. On the binding of Congo red by amyloid. J Histochem Cytochem 1962; 10: 355-364.
34. Pearson DA, Blanchette M, Baker ML, Guindon CA. Trialkylsilanes as scavengers for the trifluoroacetic acid deblocking of protecting groups in peptide synthesis. Tetrahedron Lett 1989; 30: 2739-2742.
35. Pardridge WM. CNS drug design based on principles of blood-brain barrier transport. J Neurochem 1998; 70: 1781-1792.